Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120443 · ClinicalTrials.gov registry record · NA
ivWatch Model 400: Device Validation for Non-Infiltrated Tissues
A NA study of Infiltration of Peripheral IV Therapy, sponsored by ivWatch.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT02120443: Completed NA study of Infiltration of Peripheral IV Therapy, sponsored by ivWatch.
NCT02120443 is a NA study of Infiltration of Peripheral IV Therapy that has completed, run by ivWatch. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02120443, a NA study of Infiltration of Peripheral IV Therapy, has completed, sponsored by ivWatch.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
A single arm study of 40 adult volunteers to assess the safety and efficacy of the ivWatch Model 400 when observing non-infiltrated (normal) tissues at common peripheral IV therapy sites.
Primary Outcome
The ivWatch Model 400 issues red notifications to communicate the need for a clinician to check an IV site. A red notification suggests an increased likelihood that an IV infiltration may be occurring, with a greater likelihood relative to a yellow notification. This measure describes the average number of red notifications issued by the ivWatch device in a given day when monitoring normal, non-infiltrated tissues. The 95% confidence interval for the red notification rate was calculated using th
Conditions Studied
Interventions
- DEVICE ivWatch Model 400
Study Locations (1)
Virginia
- ivWatch, LLC - Williamsburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-01 |
| Phase | NA |
What the finished NCT02120443 record still lists
NCT02120443 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Infiltration of Peripheral IV Therapy appearing as the primary indexed condition, and to 1 intervention - of which ivWatch Model 400 is the first listed.
NCT02120443 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT02120443 about?
NCT02120443 is a clinical study titled "ivWatch Model 400: Device Validation for Non-Infiltrated Tissues". A single arm study of 40 adult volunteers to assess the safety and efficacy of the ivWatch Model 400 when observing non-infiltrated (normal) tissues at common peripheral IV therapy sites.
What is the current status of trial NCT02120443?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2014-01. Estimated completion is 2014-01.
What conditions does trial NCT02120443 study?
This clinical trial studies the following conditions: Infiltration of Peripheral IV Therapy.
What interventions are being tested in trial NCT02120443?
The interventions under investigation include: ivWatch Model 400 (DEVICE).
Who is sponsoring clinical trial NCT02120443?
This trial is sponsored by ivWatch, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02120443 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infiltration of Peripheral IV Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02120443's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia